Evidence map›Paper›PMID 40428374›Full record

ReviewGenes2025

Non-Invasive Preimplantation Genetic Testing.

Daniela N Bakalova, Luis Navarro-Sánchez, Carmen Rubio

Abstract readReview
In one paragraph

Review in Genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Observational
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Daniela N BakalovaIgenomix (Part of Vitrolife Group), R&D Genetic Services, 46980 Paterna, Valencia, Spain.ORCID 0000-0003-1853-0408
Luis Navarro-SánchezIgenomix (Part of Vitrolife Group), R&D Genetic Services, 46980 Paterna, Valencia, Spain.
Carmen RubioIgenomix (Part of Vitrolife Group), R&D Genetic Services, 46980 Paterna, Valencia, Spain.ORCID 0000-0003-1522-6152

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To minimise the influence of chromosomal abnormalities during IVF treatment, embryos can be screened before transfer using preimplantation genetic testing. This typically involves an invasive trophectoderm biopsy at the blastocyst stage, where 4-8 cells are collected and analysed. However, emerging evidence indicates that, as embryos develop in vitro in culture media, they release cell-free DNA into the media, providing an alternative source of genetic material that can be accessed non-invasively. Spent blastocyst media samples that contain embryo cell-free DNA demonstrate high informativity rates and ploidy concordance when compared with the corresponding trophectoderm, inner cell mass, or whole blastocyst results. However, optimising this non-invasive approach requires several changes to embryo culture protocols, including additional embryo washes to tackle contamination and extending embryo culture time to maximise the amount of cell-free DNA released into the culture media. In this review, we discuss this novel non-invasive approach for aneuploidy detection and embryo prioritisation, as well as the current data and future prospects for utilising cell-free DNA analysis to identify structural rearrangements and single gene disorders.

Indexed as

BlastocystCell-Free Nucleic AcidsGenetic TestingPreimplantation DiagnosisAneuploidyEmbryo Culture TechniquesFemaleFertilization in VitroHumansPregnancyCell-Free Nucleic Acidsaneuploidyblastocystcell-free DNAculture mediumnon-invasive PGT

Identifiers

PMID40428374
PMCPMC12111310

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.